Navigation Links
Researchers discover new risk factor for cardiovascular disease, and a way to control it

This release is available in French.

Montreal, November 9th 2008 - A team of international researchers including scientists from the McGill University Health Centre (MUHC) and McGill University have discovered that having high levels of particular protein puts patients at increased risk of developing cardiovascular disease. The results of the study were so conclusive that the clinical trial had to be stopped before its scheduled completion date.

Researchers associated with the international JUPITER Project have demonstrated that high levels of high-sensitivity C-reactive protein (hs-CRP) leads to increased risk of cardiovascular disease. This risk decreases by up to 44% if the patients are treated with statin medications.

Dr. Jacques Genest, of the Research Institute of the MUHC and McGill's Faculty of Medicine led the Canadian component of the JUPITER clinical study, which was initiated by Dr. Paul Ridker of the Harvard University Faculty of Medicine.

"The risk of cardiovascular disease due to increased hs-CRP levels has been greatly underestimated until now," according to Dr Genest. "Our results show that this is an extremely important indicator that doctors will have to consider in the future."

"We hope that this study will prompt a review of current clinical practices, especially in terms of screening and prevention in adults," he added. "However, we still need to do more research to establish specific standards."

The JUPITER study included 17,802 patients from 27 different countries. All had normal levels of cholesterol (LDL-c) and high levels of hs-CRP, and according to current standards, were not considered "at risk" for cardiovascular events, and were therefore not receiving any treatment. During the study, participants received a daily dose of the statin drug rosuvastin, and its consequences were striking: a 44% decrease in the risk of cardiovascular disease and a 21% decrease in mortality.

"These results definitely surpassed our predictions," said Dr. Genest. "We had to stop the study before its scheduled completion, as the benefit of the treatment for the selected patients was so great that we needed to present our findings to the medical community as soon as possible."

Since statins have a cholesterol-lowering effect, they are currently used to prevent cardiovascular disease in patients who are at-risk due to high LDL-c levels. But cardiovascular disease is also caused by vascular inflammation, which is marked by levels of hs-CRP. This study shows that statins indeed act on both cholesterol and inflammation, an effect that has long been suspected but not proven.


Contact: Isabelle Kling
McGill University Health Centre

Related medicine news :

1. First Study of War-Related Mental Disorders Among Iraqis 10 Years Post-Gulf War Published by Researchers at Wayne State University and Basrah University, Iraq
2. Researchers find predictive tests and early treatment delay progression of blood cell cancer
3. Researchers describe how chronic inflammation can lead to stomach cancer
4. Researchers ID Genetic Markers for Esophageal Cancer
5. Researchers identify mechanism, possible drug treatment for tumors in neurofibromatosis
6. Cancer requires support from immune system to develop, UT Southwestern researchers report
7. Researchers find new chemical key that could unlock hundreds of new antibiotics
8. Penn researchers find key to Sonic hedgehog control of brain development
9. Temple researchers look for behavioral link between breastfeeding and lower risk of obesity
10. MU researchers advance health communication for at-risk populations
11. Researchers Find More Genes Linked to Lung Cancer
Post Your Comments:
(Date:10/13/2015)... ... , ... Sir Grout of Greater Boston donated an expansive, seven room ... House Charities® (RMHC®). This donation was made in an effort to give back to ... inception. , “We believe strongly in the Ronald McDonald House Charities, and they are ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... its newest technology platform, ENGAGE, at HIMSS’s Patient Engagement Summit . HealthAware ... , ENGAGE delivers innovative health programs and interventions via mobile devices that provide ...
(Date:10/13/2015)... ... October 13, 2015 , ... Element ... products, introduced a new company, RightSensor™ LLC, an Internet of Things (IoT) hardware ... RightSensor™ provides a fully-managed approach for customers requiring sensor hardware for critical data ...
(Date:10/13/2015)... ... , ... NavaFit Inc. today announced the launch of its NavaFit app for ... local fitness & sporting events, and stay motivated. Users can download the ... us to get more serious about fitness and wellness, individuals are constantly looking for ...
(Date:10/13/2015)... , ... October 13, 2015 ... ... Omega-3, a first-of-its kind product that targets the unique health needs of ... of the American Pregnancy Association ( ), utilizes Nordic Naturals’ exclusive, ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... , Oct. 13, 2015  A minimally-invasive treatment just ... the United States.  After more than 10 years of ... 9 approved the use of High Intensity Focused Ultrasound ... cells while protecting surrounding tissue and minimizing chances for ... George Suarez , a pioneering Miami ...
(Date:10/13/2015)... N.J. , Oct. 13, 2015  ContraVir ... the "Company"), a biopharmaceutical company focused on the ... announced the closing of its previously announced underwritten ... stock and warrants to purchase up to 3,000,000 ... fixed combined price to the public of $3.00. ...
(Date:10/13/2015)... , Oct. 13, 2015  Measurement in accountable ... and balancing financial incentives, but gaps in measurement ... care and health systems. A new, peer-reviewed ... Managed Care explores measurement gaps for ... sets. --> --> ...
Breaking Medicine Technology: